Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2020. The company is hosting a conference call at 4:30 p.m. EST to discuss results.

Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results

Pasadena. CA | Posted on November 23rd, 2020

Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 8492751.

A replay of the webcast will be available on the company’s website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 8492751.

Selected Recent Events

Earned a $20 million milestone payment from Amgen following the administration of the first dose of AMG 890, now called olpasiran, in a Phase 2 clinical study
Hosted a key opinion leader webinar on ARO-ENaC, the company’s investigational RNAi therapeutic being developed as a treatment for patients with cystic fibrosis
Initiated a Phase 1b study of ARO-HIF2, the company’s first tumor targeted investigational RNAi therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma
Presented new clinical data from Phase 1/2 studies of both wholly owned cardiometabolic candidates, ARO-APOC3 and ARO-ANG3, at multiple medical meetings, including the European Society of Cardiology and the American Heart Association meetings, and subsequently hosted key opinion leader webinars to discuss the data and plans for future development of the product candidates
Presented new clinical data at The Liver Meeting Digital Experience, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) on ARO-AAT, Arrowhead’s candidate against liver disease associated with alpha-1 antitrypsin deficiency, showing that ARO-AAT strongly reduced the production of mutant Z-AAT protein and led to improvements in multiple biomarkers of alpha-1 liver disease
Signed an agreement with Takeda to co-develop and co-commercialize ARO-AAT, which includes $300 million upfront, $740 million in potential milestone payments, a 50/50 profit sharing agreement in the U.S., and 20-25% royalty on sales outside the U.S.
Selected Fiscal Year 2020 Financial Results

ARROWHEAD PHARMACEUTICALS, INC.

CONSOLIDATED CONDENSED FINANCIAL INFORMATION

















Year Ended September 30,



OPERATING SUMMARY

2020



2019

















REVENUE

$

87,992,066





$

168,795,577



OPERATING EXPENSES













Research and development



128,874,979







81,048,686



General and administrative expenses



52,275,890







26,556,257



TOTAL OPERATING EXPENSES



181,150,869







107,604,943



OPERATING INCOME (LOSS)



(93,158,803

)





61,190,634



OTHER INCOME/(EXPENSE), PROVISION FOR INCOME TAXES



8,605,577







6,784,215



NET INCOME (LOSS)

$

(84,553,226

)



$

67,974,849

















NET INCOME (LOSS) PER SHARE (DILUTED)

$

(0.84

)



$

0.69



WEIGHTED AVERAGE SHARES OUTSTANDING (DILUTED)



100,722,224







98,607,815

















FINANCIAL POSITION SUMMARY

September 30,



September 30,





2020



2019



CASH AND CASH EQUIVALENTS

$

143,582,667





$

221,804,128



SHORT-TERM INVESTMENTS AND MARKETABLE SECURITIES



171,909,470







36,899,894



LONG-TERM INVESTMENTS



137,486,883







44,175,993



TOTAL CASH RESOURCES (CASH AND INVESTMENTS)



452,979,020







302,880,015



OTHER ASSETS



69,524,723







46,965,422



TOTAL ASSETS



522,503,743







349,845,437



TOTAL CURRENT DEFERRED REVENUE



19,291,075







77,769,629



TOTAL LONG TERM DEFERRED REVENUE



-







5,035,142



OTHER LIABILITIES



41,433,536







23,004,414



TOTAL LIABILITIES



60,724,611







105,809,185



TOTAL STOCKHOLDERS' EQUITY



461,779,132







244,036,252



TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

$

522,503,743





$

349,845,437

















SHARES OUTSTANDING



102,376,303







95,506,271



####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Media:
LifeSci Communications, LLC
Josephine Belluardo, Ph.D.
646-751-4361

www.lifescicommunications.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Wearable sensors that detect gas leaks April 19th, 2021

JEOL USA Welcomes New Managing Director, Hidetaka Sawada April 19th, 2021

FSU engineers improve performance of high-temperature superconductor wires April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

French & Swiss Scientists Demonstrate ‘All-in-One’ Technique that Could Accelerate Phage-Therapy Diagnosis: Lensless Imaging System Affirms Phage Therapy’s Value in Treating Serious Infection, Tracks Phage Resistance and Could Easily Be Implemented in Compact Devices at Phage Lab April 13th, 2021

Antibody binding-site conserved across COVID-19 virus variants: The structural revelation could have implications as a therapeutic target in all SARS-CoV-2 variants April 9th, 2021

Announcements

Wearable sensors that detect gas leaks April 19th, 2021

JEOL USA Welcomes New Managing Director, Hidetaka Sawada April 19th, 2021

FSU engineers improve performance of high-temperature superconductor wires April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Financial Reports

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

180 Degree Capital Corp. to Report Fourth Quarter 2020 Financial Results on Monday, February 22, 2021 and to Host a Conference Call on Tuesday, February 23, 2021 February 19th, 2021

Events/Classes

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

CEA-Leti Envisions Widespread Use of LiDAR Systems Based on Integrated Optical Phased Arrays (OPAs): OPAs with Solid-State Beam Steering Can Reduce the Cost and Size of LiDAR Systems & Improve Performance; Results Reported at Photonics West 2021 March 9th, 2021

CEA-Leti Announces 16 Papers to Be Presented At Photonics West 2021 and a Virtual Workshop on March 25 March 3rd, 2021

Nanobiotechnology

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

French & Swiss Scientists Demonstrate ‘All-in-One’ Technique that Could Accelerate Phage-Therapy Diagnosis: Lensless Imaging System Affirms Phage Therapy’s Value in Treating Serious Infection, Tracks Phage Resistance and Could Easily Be Implemented in Compact Devices at Phage Lab April 13th, 2021

Energy transmission by gold nanoparticles coupled to DNA structures April 9th, 2021

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project